Citations (64)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Renato Vellucci & Diego Fornasari. (2023) Appropriate use of tapentadol: focus on the optimal tapering strategy. Current Medical Research and Opinion 39:1, pages 123-129.
Read now
Read now
R. Freynhagen, C. Elling, T. Radic, M. Sohns, H. Liedgens, D. James, R. McCool & M. Edwards. (2021) Safety of tapentadol compared with other opioids in chronic pain treatment: network meta-analysis of randomized controlled and withdrawal trials. Current Medical Research and Opinion 37:1, pages 89-100.
Read now
Read now
Alain Serrie, Bernd Lange & Achim Steup. (2017) Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study. Current Medical Research and Opinion 33:8, pages 1423-1432.
Read now
Read now
Stephan A Schug & Chandani Chandrasena. (2015) Pain management of the cancer patient. Expert Opinion on Pharmacotherapy 16:1, pages 5-15.
Read now
Read now
Sebastiano Mercadante, Giampiero Porzio, Claudio Adile, Federica Aielli, Andrea Cortegiani, Anthony Dickenson & Alessandra Casuccio. (2014) Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain. Current Medical Research and Opinion 30:10, pages 2063-2068.
Read now
Read now
Michael J Brennan. (2013) Update on prescription extended-release opioids and appropriate patient selection. Journal of Multidisciplinary Healthcare 6, pages 265-280.
Read now
Read now
Robert B Raffa, Helmut Buschmann, Thomas Christoph, Gary Eichenbaum, Werner Englberger, Christopher M Flores, Torsten Hertrampf, Babette Kögel, Klaus Schiene, Wolfgang Straßburger, Rolf Terlinden & Thomas M Tzschentke. (2012) Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opinion on Pharmacotherapy 13:10, pages 1437-1449.
Read now
Read now
Craig T Hartrick & Jose Rafael Rodríguez Hernandez. (2012) Tapentadol for pain: a treatment evaluation. Expert Opinion on Pharmacotherapy 13:2, pages 283-286.
Read now
Read now
Articles from other publishers (56)
Shane Darke, Johan Duflou, Amy Peacock, Michael Farrell & Julia Lappin. (2022) Characteristics of fatal tapentadol‐related toxicity in Australia. Drug and Alcohol Review 41:5, pages 1071-1077.
Crossref
Crossref
Preeti Manandhar, Mark Connor & Marina Santiago. (2022) Tapentadol shows lower intrinsic efficacy at µ receptor than morphine and oxycodone. Pharmacology Research & Perspectives 10:1.
Crossref
Crossref
Bart J Morlion, César Margarit, Imane Wild, Ravi Karra, Hiltrud Liedgens, Melanie Sohns & Gabriele Finco. (2021) Bone fractures in patients using tapentadol or oxycodone: an exploratory US claims database study. Pain Management 11:1, pages 39-47.
Crossref
Crossref
Barbara Kosińska, Paweł Turczyn, Krzysztof Wesołowski, Beata Tarnacka & Małgorzata Malec-Milewska. (2020) Central sensitization in chronic lumbar spine pain – possibilities of therapeutic interventions. BÓL 21:2, pages 45-53.
Crossref
Crossref
Xinyi Wang, Sujita W. Narayan, Jonathan Penm & Asad E. Patanwala. (2020) Efficacy and Safety of Tapentadol Immediate Release for Acute Pain. The Clinical Journal of Pain 36:5, pages 399-409.
Crossref
Crossref
Amy Peacock, Natasa Gisev, Sonja Memedovic, Briony Larance, Jared Brown, Rose Cairns, Nicholas Buckley, Michael Farrell & Louisa Degenhardt. (2020) Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study. Drug and Alcohol Dependence 206, pages 107697.
Crossref
Crossref
Carlos A. Pino. 2019. Cancer. Cancer
481
497
.
Ramagonolla Kranthikumar, Prathama S. Mainkar, Genji Sukumar, Rambabu Chegondi & Srivari Chandrasekhar. (2019) Tetrahydrothiopyran-4-one as Five-Carbon Source for Scalable Synthesis of (±)-Tapentadol. Organic Process Research & Development 23:7, pages 1369-1373.
Crossref
Crossref
Imane Belcaid & Naveen Eipe. (2019) Perioperative Pain Management in Morbid Obesity. Drugs 79:11, pages 1163-1175.
Crossref
Crossref
Robert B. Raffa, Christian Elling & Thomas M. Tzschentke. (2018) Does ‘Strong Analgesic’ Equal ‘Strong Opioid’? Tapentadol and the Concept of ‘µ-Load’. Advances in Therapy 35:10, pages 1471-1484.
Crossref
Crossref
Renata Zajączkowska, Barbara Przewłocka, Magdalena Kocot-Kępska, Joanna Mika, Wojciech Leppert & Jerzy Wordliczek. (2018) Tapentadol – A representative of a new class of MOR-NRI analgesics. Pharmacological Reports 70:4, pages 812-820.
Crossref
Crossref
Joseph V. PergolizziJrJr, Robert TaylorJrJr, Jo Ann LeQuang, Robert B. Raffa & John Bisney. (2018) Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain. Pain and Therapy 7:1, pages 37-57.
Crossref
Crossref
Amy Peacock, Briony Larance, Michael Farrell, Rose Cairns, Nicholas Buckley & Louisa Degenhardt. (2018) Opioid use and harms associated with a sustained-release tapentadol formulation: a postmarketing study protocol. BMJ Open 8:3, pages e020006.
Crossref
Crossref
L. Arendt‐Nielsen, B. Morlion, S. Perrot, A. Dahan, A. Dickenson, H.G. Kress, C. Wells, D. Bouhassira & A. Mohr Drewes. (2017) Assessment and manifestation of central sensitisation across different chronic pain conditions. European Journal of Pain 22:2, pages 216-241.
Crossref
Crossref
Juan R. Zapata-Morales, Ángel J. Alonso-Castro, Vinicio Granados-Soto, Sergio Sánchez-Enriquez & Mario A. Isiordia-Espinoza. (2018) Assessment of the antinociceptive and ulcerogenic activity of the tapentadol-diclofenac combination in rodents. Drug Development Research 79:1, pages 38-44.
Crossref
Crossref
Michael Saulino. 2018. Challenging Neuropathic Pain Syndromes. Challenging Neuropathic Pain Syndromes
167
175
.
Heath B. McAnallyHeath B. McAnally. 2018. Opioid Dependence. Opioid Dependence
73
97
.
Gabriel Calvo Mosquera, Dania Calvo Rodríguez & Amparo González Cal. (2017) Abordaje multifactorial del dolor crónico no neoplásico en Atención Primaria. FMC - Formación Médica Continuada en Atención Primaria 24, pages 1-55.
Crossref
Crossref
Edvina Galiè, Veronica Villani, Irene Terrenato & Andrea Pace. (2017) Tapentadol in neuropathic pain cancer patients: a prospective open label study. Neurological Sciences 38:10, pages 1747-1752.
Crossref
Crossref
Joseph V PergolizziJrJr, Frank Breve, Robert TaylorJrJr, Robert B Raffa, Stephani E Strasburger & Jo Ann LeQuang. (2017) Considering tapentadol as a first-line analgesic: 14 questions. Pain Management 7:4, pages 331-339.
Crossref
Crossref
Ralf Baron, Leopold Eberhart, Kai-Uwe Kern, Stefan Regner, Roman Rolke, Christian Simanski & Thomas Tölle. (2017) Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data. Pain Practice 17:5, pages 678-700.
Crossref
Crossref
Silvia FranchiGiada AmodeoMarta GandollaGiorgia MoschettiAlberto Emilio PaneraiPaola Sacerdote. (2017) Effect of Tapentadol on Splenic Cytokine Production in Mice. Anesthesia & Analgesia 124:3, pages 986-995.
Crossref
Crossref
Christoph Maier, Doris Kindler, Hans-Christoph Diener, Tina Mainka, Marcus Gerwig & Ulrike Bingel. 2017. Schmerztherapie. Schmerztherapie
391
483
.
Alexios Carayannopoulos. 2017. Comprehensive Pain Management in the Rehabilitation Patient. Comprehensive Pain Management in the Rehabilitation Patient
373
402
.
Peter Keogh & Vivek Mehta. (2016) Recent Advances in the Pharmacological Management of Neuropathic Pain. Current Anesthesiology Reports 6:4, pages 327-333.
Crossref
Crossref
Mazzola Rosario, Ricchetti Francesco, Fersino Sergio, Giaj Levra Niccol?Fiorentino Alba, Nicodemo Maurizio, Albanese Sergio, Gori Stefania & Alongi Filippo. (2016) Effectiveness of tapentadol prolonged release for the management of painful mucositis in head and neck cancers during intensity modulated radiation therapy. Supportive Care in Cancer 24:10, pages 4451-4455.
Crossref
Crossref
Judith A. PaiceRussell PortenoyChristina LacchettiToby CampbellAndrea ChevilleMarc CitronLouis S. ConstineAndrea CooperPaul GlareFrank KeefeLakshmi KoyyalaguntaMichael LevyChristine MiaskowskiShirley Otis-GreenPaul SloanEduardo Bruera. (2016) Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology 34:27, pages 3325-3345.
Crossref
Crossref
Flaminia Coluzzi, Robert TaylorJr.Jr., Joseph V. PergolizziJr.Jr., Consalvo Mattia & Robert B. Raffa. (2016) Good clinical practice guide for opioids in pain management: the three Ts – titration (trial), tweaking (tailoring), transition (tapering). Brazilian Journal of Anesthesiology (English Edition) 66:3, pages 310-317.
Crossref
Crossref
Flaminia Coluzzi, Robert TaylorJr.Jr., Joseph V. PergolizziJr.Jr., Consalvo Mattia & Robert B. Raffa. (2016) Orientação para boa prática clínica para opioides no tratamento da dor: os três “Ts” – titulação (teste), ajustes (individualização), transição (redução gradual). Brazilian Journal of Anesthesiology 66:3, pages 310-317.
Crossref
Crossref
Olfat Zekry & Charles A. Inderjeeth. (2015) Comment on “Pain in the Frail or Elderly Patient: Does Tapentadol Have a Role?”. Drugs & Aging 32:10, pages 871-873.
Crossref
Crossref
Felicity C. Veal & Gregory M. Peterson. (2015) Pain in the Frail or Elderly Patient: Does Tapentadol Have a Role?. Drugs & Aging 32:6, pages 419-426.
Crossref
Crossref
Leonor Gonçalves, Lauren V. Friend & Anthony H. Dickenson. (2015) The influence of μ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy. European Journal of Pharmacology 749, pages 151-160.
Crossref
Crossref
W. Häuser, F. Bock, P. Engeser, G. Hege-Scheuing, M. Hüppe, G. Lindena, C. Maier, H. Norda, L. Radbruch, R. Sabatowski, M. Schäfer, M. Schiltenwolf, M. Schuler, H. Sorgatz, T. Tölle, A. Willweber-Strumpf & F. Petzke. (2015) Empfehlungen der aktualisierten Leitlinie LONTSRecommendations of the updated LONTS guidelines. Der Schmerz 29:1, pages 109-130.
Crossref
Crossref
R. Lauche, P. Klose, L. Radbruch, P. Welsch & W. Häuser. (2014) Opioide bei chronischen nicht-tumorbedingten Schmerzen – gibt es Unterschiede?Opioids in chronic noncancer pain—are opioids different?. Der Schmerz 29:1, pages 73-84.
Crossref
Crossref
R.-D. Treede & M. Zenz. (2014) Langzeitanwendung von Opioiden bei chronischen nicht tumorbedingten Schmerzen (LONTS 2)Long-term application of opioids in chronic noncancer pain (LONTS 2). Der Schmerz 29:1, pages 5-7.
Crossref
Crossref
S. Falk, R. Patel, A. Heegaard, S. Mercadante & A.H. Dickenson. (2015) Spinal neuronal correlates of tapentadol analgesia in cancer pain: A back-translational approach. European Journal of Pain 19:2, pages 152-158.
Crossref
Crossref
John L. Clifford, Marcie Fowler, Jacob J. Hansen, Bopiah Cheppudira, Jennifer E. Nyland, Margaux M. Salas, Laura L. McGhee, Lawrence N. Petz & Dayna R. Loyd. (2014) State of the science review. Journal of Trauma and Acute Care Surgery 77:3, pages S228-S236.
Crossref
Crossref
A. Cowan, R.B. Raffa, C.S. Tallarida, R.J. Tallarida, T. Christoph, W. Schröder & T.M. Tzschentke. (2014) Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit. European Journal of Pain 18:8, pages 1148-1156.
Crossref
Crossref
David BorsookRichard HargreavesChas BountraFrank Porreca. (2014) Lost but making progress—Where will new analgesic drugs come from?. Science Translational Medicine 6:249.
Crossref
Crossref
Sebastiano MercadanteGiampiero PorzioVittorio Gebbia. (2014) New Opioids. Journal of Clinical Oncology 32:16, pages 1671-1676.
Crossref
Crossref
Vasco Meneghini, Bruna Cuccurazzu, Valeria Bortolotto, Vera Ramazzotti, Federica Ubezio, Thomas M. Tzschentke, Pier Luigi Canonico & Mariagrazia Grilli. (2014)
The Noradrenergic Component in Tapentadol Action Counteracts
μ
-Opioid Receptor–Mediated Adverse Effects on Adult Neurogenesis
. Molecular Pharmacology 85:5, pages 658-670.
Crossref
Crossref
Michael Saulino. (2014) Spinal Cord Injury Pain. Physical Medicine and Rehabilitation Clinics of North America 25:2, pages 397-410.
Crossref
Crossref
Deepti Jain & Pawan Kumar Basniwal. (2013) Tapentadol, a novel analgesic: Review of recent trends in synthesis, related substances, analytical methods, pharmacodynamics and pharmacokinetics. Bulletin of Faculty of Pharmacy, Cairo University 51:2, pages 283-289.
Crossref
Crossref
Wojciech Leppert. 2013. Neuropathic Pain. Neuropathic Pain
191
204
.
. 2013. Neuropathic Pain. Neuropathic Pain
177
216
.
Michael A. Überall. (2013) Chancen optimieren, Risiken minimieren. MMW - Fortschritte der Medizin 155:25, pages 63-71.
Crossref
Crossref
Li Khai Daniel Phang & Kian Hian Tan. (2013) Current pharmacological modalities for control of chronic non-cancer pain. Trends in Anaesthesia and Critical Care 3:5, pages 283-288.
Crossref
Crossref
William W. Stoops, Paul E. A. Glaser & Craig R. Rush. (2013) Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users. Psychopharmacology 228:2, pages 255-262.
Crossref
Crossref
B. Michot, S. Bourgoin, V. Kayser & M. Hamon. (2013) Effects of tapentadol on mechanical hypersensitivity in rats with ligatures of the infraorbital nerve versus the sciatic nerve. European Journal of Pain 17:6, pages 867-880.
Crossref
Crossref
Donghu Bai, Sha‐Hua Huang, Zuming Lin, Lin Yang, Junzeng Dai, Meng‐Yuan Huang, Xueshun Jia & Ran Hong. (2013) Aza‐Belluš‐Claisen Rearrangement‐Enabled Synthesis of Racemic Tapentadol and Its Stereoisomers. Chinese Journal of Chemistry 31:3, pages 317.
Crossref
Crossref
Robert Taylor, Joseph V. Pergolizzi & Robert B. Raffa. (2013) Tapentadol Extended Release for Chronic Pain Patients. Advances in Therapy 30:1, pages 14-27.
Crossref
Crossref
Marie Fallon. 2013. Cancer Pain. Cancer Pain
153
164
.
Florent Viguier, Beno?t Michot, Val?rie Kayser, Jean-Fran?ois Bernard, Jos?-Miguel Vela, Michel Hamon & Sylvie Bourgoin. (2012) GABA, but not opioids, mediates the anti-hyperalgesic effects of 5-HT7 receptor activation in rats suffering from neuropathic pain. Neuropharmacology 63:6, pages 1093-1106.
Crossref
Crossref
Robert F WolffKim Reid, Marcello di Nisio, Dagfinn Aune, Carla Truyers, Adrian V Hernandez, Kate Misso, Rob Riemsma & Jos Kleijnen. (2012) Systematic review of adverse events of buprenorphine patch versus fentanyl patch in patients with chronic moderate-to-severe pain. Pain Management 2:4, pages 351-362.
Crossref
Crossref
Qiang Zhang, Jian-Feng Li, Guang-Hui Tian, Rong-Xia Zhang, Jin Sun, Jin Suo, Xin Feng, Du Fang, Xiang-Rui Jiang & Jing-Shan Shen. (2012) A practical and enantioselective synthesis of tapentadol. Tetrahedron: Asymmetry 23:8, pages 577-582.
Crossref
Crossref
Sheridan M. Hoy. (2012) Tapentadol Extended Release. Drugs 72:3, pages 375-393.
Crossref
Crossref